A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)

Phase 2 Not yet recruiting 42 enrolled Alberto Esquenazi Bristol Meyer Squibb · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368

Timeline

Start: 2026-07
Primary completion: 2027-06
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986368	Unknown	6 mg	Oral

Indications

No indication recorded.